These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 16544268)

  • 21. [Infections caused by multiresistant bacteria].
    Zahar JR; Ferroni A
    Rev Prat; 2006 Sep; 56(13):1397-404. PubMed ID: 17002063
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Successful treatment of a patient with multidrug resistant Acinetobacter baumannii meningitis with high dose ampicillin-sulbactam].
    Sayin Kutlu S; Saçar S; Süzer T; Cevahir N; Okke D; Dirgen Caylak S; Turgut H
    Mikrobiyol Bul; 2008 Apr; 42(2):353-8. PubMed ID: 18697435
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vivo selection of Enterobacter aerogenes with reduced susceptibility to cefepime and carbapenems associated with decreased expression of a 40 kDa outer membrane protein and hyperproduction of AmpC beta-lactamase.
    Fernández-Cuenca F; Rodríguez-Martínez JM; Martínez-Martínez L; Pascual A
    Int J Antimicrob Agents; 2006 Jun; 27(6):549-52. PubMed ID: 16697150
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimizing therapy for infections caused by enterobacteriaceae producing extended-spectrum beta-lactamases.
    Endimiani A; Paterson DL
    Semin Respir Crit Care Med; 2007 Dec; 28(6):646-55. PubMed ID: 18095228
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Extended-spectrum beta-lactamases. An overview.
    Patterson JE
    Postgrad Med; 2001 Feb; 109(2 Suppl):32-8. PubMed ID: 19667555
    [TBL] [Abstract][Full Text] [Related]  

  • 26. beta-Lactams without a suicide inhibitor.
    Giamarellou H
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():194-7. PubMed ID: 18154547
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Control of extended-spectrum {beta}-lactamase-producing Klebsiella pneumoniae using a computer-assisted management program to restrict third-generation cephalosporin use.
    Kim JY; Sohn JW; Park DW; Yoon YK; Kim YM; Kim MJ
    J Antimicrob Chemother; 2008 Aug; 62(2):416-21. PubMed ID: 18413317
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Redefining penems.
    Dalhoff A; Janjic N; Echols R
    Biochem Pharmacol; 2006 Mar; 71(7):1085-95. PubMed ID: 16413506
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Implementation of an infection control programme to limit the spread of extended-spectrum beta-lactamase-producing Enterobacteriaceae in a Belgian university hospital.
    Christiaens G; Barbier C; Warnotte J; Mutsers J
    J Hosp Infect; 2008 Apr; 68(4):366-7. PubMed ID: 18329138
    [No Abstract]   [Full Text] [Related]  

  • 30. In vitro susceptibility pattern of cephalosporin-resistant Gram-negative bacteria.
    Punpanich W; Tantichattanon W; Wongwatcharapaiboon S; Treeratweeraphong V
    J Med Assoc Thai; 2008 Oct; 91 Suppl 3():S21-7. PubMed ID: 19255989
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sulbactam-containing beta-lactamase inhibitor combinations.
    Akova M
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():185-8. PubMed ID: 18154545
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Extended double disc synergy testing reveals a low prevalence of extended-spectrum beta-lactamases in Enterobacter spp. in Vienna, Austria.
    Apfalter P; Assadian O; Daxböck F; Hirschl AM; Rotter ML; Makristathis A
    J Antimicrob Chemother; 2007 May; 59(5):854-9. PubMed ID: 17347178
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interventional strategies and current clinical experience with carbapenemase-producing Gram-negative bacteria.
    Akova M; Daikos GL; Tzouvelekis L; Carmeli Y
    Clin Microbiol Infect; 2012 May; 18(5):439-48. PubMed ID: 22507111
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevalence and mechanisms of cephalosporin resistance in Enterobacteriaceae in London and South-East England.
    Potz NA; Hope R; Warner M; Johnson AP; Livermore DM;
    J Antimicrob Chemother; 2006 Aug; 58(2):320-6. PubMed ID: 16735428
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Controlling the spread of carbapenemase-producing Gram-negatives: therapeutic approach and infection control.
    Carmeli Y; Akova M; Cornaglia G; Daikos GL; Garau J; Harbarth S; Rossolini GM; Souli M; Giamarellou H
    Clin Microbiol Infect; 2010 Feb; 16(2):102-11. PubMed ID: 20085604
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative in vitro activity and the inoculum effect of ertapenem against Enterobacteriaceae resistant to extended-spectrum cephalosporins.
    Betriu C; Salso S; Sánchez A; Culebras E; Gómez M; Rodríguez-Avial I; Picazo JJ
    Int J Antimicrob Agents; 2006 Jul; 28(1):1-5. PubMed ID: 16769202
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Contribution of extended-spectrum AmpC (ESAC) beta-lactamases to carbapenem resistance in Escherichia coli.
    Mammeri H; Nordmann P; Berkani A; Eb F
    FEMS Microbiol Lett; 2008 May; 282(2):238-40. PubMed ID: 18371063
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ongoing epidemic of blaVIM-1-positive Klebsiella pneumoniae in Athens, Greece: a prospective survey.
    Psichogiou M; Tassios PT; Avlamis A; Stefanou I; Kosmidis C; Platsouka E; Paniara O; Xanthaki A; Toutouza M; Daikos GL; Tzouvelekis LS
    J Antimicrob Chemother; 2008 Jan; 61(1):59-63. PubMed ID: 17999975
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes.
    Mushtaq S; Warner M; Ge Y; Kaniga K; Livermore DM
    J Antimicrob Chemother; 2007 Aug; 60(2):300-11. PubMed ID: 17548456
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antimicrobial resistance: factors and outcomes.
    Fish DN; Ohlinger MJ
    Crit Care Clin; 2006 Apr; 22(2):291-311, vii. PubMed ID: 16678001
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.